3SBio Inc.

Asia, Liaoning, China, Shenyang

Description

3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing.

Investor Profile

3SBio Inc. has made 6 investments, with 2 in the past 12 months and 33% as lead.

Stage Focus

Series A (33%)
Series B (33%)
Series Unknown (17%)
Post Ipo Debt (17%)

Country Focus

United States (50%)
China (33%)
France (17%)

Industry Focus

Medical
Biotechnology
Health Care
Therapeutics
Genetics
Health Diagnostics
Nuclear
Pharmaceutical
Biopharma

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does 3SBio Inc. frequently co-invest with?

INCE Capital

Asia, Shandong, China, Pudong

Co-Investments: 1

GL Ventures LLC

Asia, Beijing, China, Beijing

Co-Investments: 1

Octagon Capital

North America, New York, United States, New York

Co-Investments: 1

TF Capital

Asia, Shandong, China, Pudong

Co-Investments: 1

LongRiver Investments

Asia, Shanghai, China, Xuhui

Co-Investments: 1

Qiming Venture Partners

Asia, Shanghai, China, Shanghai

Co-Investments: 1

Elikon Venture

Asia, Shanghai, China, Shanghai

Co-Investments: 1

Shenzhen Capital Group

Asia, Hunan, China, Nanshan

Co-Investments: 1

What are some of recent deals done by 3SBio Inc.?

NK CellTech

Zhoupu, Shanghai, China

NK CellTech is a biotechnology company that specializes in the development of innovative technologies for treatment of NK cell therapy.

BiopharmaBiotechnologyMedical

Series ANov 22, 2024

C Ray Therapeutics

Chengdu, Sichuan, China

C Ray Therapeutics develops healthcare advancements through nuclear medicine.

Health CareHealth DiagnosticsMedicalNuclear

Series ANov 17, 2024

Amount Raised: $100,000,000

Allorion Therapeutics

Natick, Massachusetts, United States

Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.

MedicalPharmaceuticalTherapeutics

Series BMar 9, 2023

Amount Raised: $50,000,000

GenSight Biologics

Paris, Ile-de-France, France

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

BiotechnologyGeneticsHealth CareMedical

Post Ipo DebtDec 20, 2019

Amount Raised: $16,615,804

Verseau Therapeutics

Bedford, Massachusetts, United States

Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

BiotechnologyTherapeutics

Series UnknownOct 21, 2019

Amount Raised: $50,000,000

Refuge Biotechnologies

Menlo Park, California, United States

Refuge Biotechnologies therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.

BiotechnologyGeneticsHealth CareTherapeutics

Series BMay 2, 2018

Amount Raised: $25,000,000

3SBio Inc.

Description

Investor Profile

Stage Focus

Country Focus

Industry Focus

Frequently Asked Questions

Who does 3SBio Inc. frequently co-invest with?

What are some of recent deals done by 3SBio Inc.?

Ready to Raise Capital?

Pages

Free tools